These trials may attract the entire market to us the way things are going over in biotech land at the moment.
We haven't had any massive pops in a while, definitely a far cry from late 2018 with the likes of BIT or even last year with BOT, OCC etc.
On paper IHL really does seem like an incredible play for value, mostly because we are targeting multibillion dollar markets with no existing pharmotherapy already, so no competition. However, I suspect that the market is definitely risk-averse at the moment and heavy moneyflow trickling down into specs, IHL will have to substantially derisk itself by successfully achieving these trials.
I only hope the market is in a better place when we get results, because when we do I am feeling that the hype that comes with it may take most of us by surprise.
IHL Price at posting:
4.9¢ Sentiment: Buy Disclosure: Held
